Abstract
The eye is one of the targets of complications after allogeneic hematopoietic stem cell transplantation (HSCT). Most of the ocular complications after HSCT have been recognized for a long time and are well described. Dry eye syndrome after allogeneic HSCT is closely related to chronic graft-versus-host disease (cGVHD). Ocular graft-versus-host disease (GVHD) has at least three important biologic processes: lacrimal gland dysfunction, meibomian gland dysfunction, and corneoconjunctival inflammation. Ocular GVHD develops in 40-60% of patients after allogeneic HSCT. Risk factors associated with the onset of ocular GVHD included prior acute GVHD, use of mobilized blood progenitor cells, and HSCT from a female donor to a male recipient. Topical treatment plays a major role, and includes primarily lubricants and anti-inflammatory agents. Cataracts were one of the first late effects reported in patients after allogeneic HSCT. Ocular GVHD can cause prolonged morbidity affecting ADL and QOL.
Original language | English |
---|---|
Title of host publication | Blood and Marrow Transplantation Long Term Management |
Subtitle of host publication | Survivorship after Transplant: Second Edition |
Publisher | wiley |
Pages | 166-175 |
Number of pages | 10 |
ISBN (Electronic) | 9781119612780 |
ISBN (Print) | 9781119612698 |
DOIs | |
Publication status | Published - 01-01-2021 |
Externally published | Yes |
All Science Journal Classification (ASJC) codes
- General Medicine